G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 13.8 USD -2.89% Market Closed
Market Cap: 856m USD

Net Margin
GH Research PLC

0%
Current
0%
Average
4.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-42.9m
/
Revenue
0

Net Margin Across Competitors

Country Company Market Cap Net
Margin
IE
GH Research PLC
NASDAQ:GHRS
856m USD N/A
US
Eli Lilly and Co
NYSE:LLY
954.7B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
505.3B USD
27%
CH
Roche Holding AG
SIX:ROG
253.1B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
16%
CH
Novartis AG
SIX:NOVN
203.4B CHF
26%
US
Merck & Co Inc
NYSE:MRK
246.3B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
146.7B USD
16%
No Stocks Found

GH Research PLC
Glance View

Market Cap
856m USD
Industry
Pharmaceuticals

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

GHRS Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-42.9m
/
Revenue
0
What is the Net Margin of GH Research PLC?

Based on GH Research PLC's most recent financial statements, the company has Net Margin of 0%.

Back to Top